Grand Pharmaceutical Group Management
Management criteria checks 3/4
Grand Pharmaceutical Group's CEO is Chao Zhou, appointed in Jun 2021, has a tenure of 3.67 years. total yearly compensation is HK$1.87M, comprised of 90.8% salary and 9.2% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth HK$1.50M. The average tenure of the management team and the board of directors is 3.7 years and 3.7 years respectively.
Key information
Chao Zhou
Chief executive officer
HK$1.9m
Total compensation
| CEO salary percentage | 90.8% |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.01% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | HK$2b |
| Mar 31 2024 | n/a | n/a | HK$2b |
| Dec 31 2023 | HK$2m | HK$2m | HK$2b |
Compensation vs Market: Chao's total compensation ($USD240.37K) is below average for companies of similar size in the Hong Kong market ($USD515.34K).
Compensation vs Earnings: Insufficient data to compare Chao's compensation with company performance.
CEO
Chao Zhou (34 yo)
3.7yrs
Tenure
HK$1,873,000
Compensation
Mr. Chao Zhou serves as Chief Executive Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 01, 2021 and serves as its Ex...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.7yrs | HK$2.89m | 0.021% HK$ 3.1m | |
| CEO & Executive Director | 3.7yrs | HK$1.87m | 0.010% HK$ 1.5m | |
| Executive Director | 1.7yrs | HK$25.00k | no data | |
| Investor Relations Director | no data | no data | no data | |
| Executive Director | less than a year | no data | 0.017% HK$ 2.4m | |
| Company Secretary | 13.4yrs | no data | no data | |
| Chairman of Grand Pharm (China) | no data | no data | no data | |
| Vice President | no data | no data | no data |
3.7yrs
Average Tenure
51yo
Average Age
Experienced Management: 512's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.7yrs | HK$2.89m | 0.021% HK$ 3.1m | |
| CEO & Executive Director | 1.7yrs | HK$1.87m | 0.010% HK$ 1.5m | |
| Executive Director | 1.7yrs | HK$25.00k | no data | |
| Executive Director | less than a year | no data | 0.017% HK$ 2.4m | |
| Chairman of Grand Pharm (China) | no data | no data | no data | |
| Independent Non-Executive Director | 19.9yrs | HK$180.00k | no data | |
| Independent Non-Executive Director | 6.2yrs | HK$60.00k | no data | |
| Independent Non-Executive Director | 13.8yrs | HK$100.00k | no data | |
| Director of Grand Pharm (China) | 31.1yrs | no data | no data | |
| Director of Zhejiang Xianju Xianle Pharmaceutical Company Limited | no data | no data | no data | |
| Non-Executive Director | less than a year | no data | no data |
3.7yrs
Average Tenure
57yo
Average Age
Experienced Board: 512's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 08:11 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Grand Pharmaceutical Group Limited is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Yiling Chen | Guosen Securities Co., Ltd. |